Completed PHASE4 INTERVENTIONAL NCT00068029

Pegvisomant And Sandostatin LAR Combination Study

A Randomized, Parallel Group, Three-Arm Study To Evaluate Treatment With A Combination Of Pegvisomant Plus Sandostatin Lar, Pegvisomant (Alone), And Sandostatin Lar (Alone) In Patients With Acromegaly

Sponsor: Pfizer

Conditions Acromegaly

Interventions Pegvisomant Pegvisomant/ Sandostatin LAR Sandostatin LAR

Updated 6 times since 2017 Last updated: Apr 3, 2008 Started: Oct 31, 2003 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Acromegaly, this trial is completed. The trial is conducted by Pfizer and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Belfast, United Kingdom , Berlin, Germany , Boston, United States , Chapel Hill, United States , Charlottesville, United States , Col La Raza, Mexico , Darlinghurst, Australia , Dresden, Germany , Fitzroy, Australia , Fizroy, Australia and 21 more locations